logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics - Broker Appointment

RNS Number : 4056N
Silence Therapeutics PLC
20 May 2020
 

Appointment of New Nominated Adviser and Broker

 

20 May 2020

 

LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces the appointment of Investec Bank plc as the Company's Nominated Adviser and sole Broker, effective immediately.

 

 

 

For more information, please contact:

 

Silence Therapeutics plc

Iain Ross, Executive Chairman

Rob Quinn, Chief Financial Officer

 

 

Tel:  +44 (0)20 3457 6900

Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 

Tel:  +44 (0) 20 7597 5970

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]

 

Tel: +44 (0) 20 3709 5700

U.S. IR

Westwicke

Peter Vozzo

[email protected]

 Tel: +1 (443) 213-0505

 

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPGPUPGAUPUGBB

Quick facts: Silence Therapeutics PLC

Price: 457

Market: AIM
Market Cap: £378.52 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics feels move to NASDAQ will give its tech the...

Silence Therapeutics PLC's (LON:SLN) chairman Iain Ross and CFO Rob Quinn speak to Proactive London's Andrew Scott after announcing its intention to list on the American growth market, Nasdaq. Ross says in the US, RNAi is very hot at the moment and if you look at their competitor companies...

on 22/5/20